SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is facing significant volatility as investors weigh strong earnings and revenue growth against concerns over high AI capital expenditure requirements. The community remains divided between those betting on a long-term turnaround fueled by foundry progress and those skeptical of the recent post-earnings price reversal.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending as investors brace for an FDA advisory committee meeting this week that will determine the regulatory future of several key peptides, a major potential growth catalyst for the company. Community discussion is split between those viewing the volatility as a strategic dip-buying opportunity and bears who are highlighting increased short interest and executive share sales.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is experiencing significant volatility and high trading volume as investors closely watch the ongoing proxy battle between management and former CEO Toby Neugebauer alongside anticipation for a major anchor tenant announcement. The community is actively debating the impact of upcoming governance votes and the potential for a massive upside catalyst tied to its large-scale power infrastructure projects in Texas.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending following a negative opinion from the EMA's CHMP regarding the marketing authorization for its flagship drug, prompting the company to request a re-examination. Community discussion is focused on the potential impact of this regulatory setback on the company's long-term valuation, while some investors view the resulting price volatility as a buying opportunity given the firm's existing U.S. revenue and cash position.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is facing intense downward pressure and high volatility as investors react to a lackluster earnings report and persistent skepticism regarding the company's autonomous vehicle timelines. The community remains deeply divided, with bears aggressively shorting the stock while vocal bulls continue to call for a reversal, pinning their hopes on future robotics potential and institutional accumulation near key psychological support levels.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending as investors react to a new device-leasing partnership with Klarna while the community remains divided over its AI strategy, with bulls praising the company's capital discipline and bears criticizing its lack of innovation. The stock continues to see heavy options activity and day-trading interest as market participants debate whether its current valuation is sustainable amidst broader tech sector rotation.

MP Materials Corp. engages in the production and marketing of rare earth specialty materials. It operates through the following segments: Materials and Magnetics. The Materials segment focuses on the operation of Mountain Pass, which produces refined rare earth oxides and related products, as well as rare earth concentrate products. The Magnetics segment is involved in the operation of Independence Facility, where the company began production of magnetic precursor products. The company was founded by James Henry Litinsky and Michael Rosenthal in 2017 and is headquartered in Las Vegas, NV.

MP Materials Corporation

MP Materials is facing significant downward pressure as investors react to China adding the company to its export control list, fueling concerns over supply chain access and geopolitical tension. Despite this volatility, the community remains deeply divided, with many long-term holders highlighting strong institutional support, government contracts, and recent insider buying as indicators that the current pullback represents a strategic opportunity.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as investors react to escalating regional conflicts in the Middle East, particularly around critical shipping lanes in the Strait of Hormuz and Red Sea. Community members are actively debating the long-term impact of supply chain disruptions, dwindling strategic reserves, and whether current energy prices adequately reflect the risks of a prolonged geopolitical standoff.

Deckers Outdoor Corp. engages in the business of designing, marketing, and distributing footwear, apparel, and accessories developed for both everyday casual lifestyle use and high performance activities. It operates through the following segments: UGG Brand, HOKA Brand, Teva Brand, Sanuk Brand, Other Brands, and Direct-to-Consumer. The UGG Brand segment offers a line of premium footwear, apparel, and accessories. The HOKA Brand segment sells footwear and apparel that offers enhanced cushioning and inherent stability with minimal weight, originally designed for ultra-runners. The Teva Brand segment focuses on the sport sandal and modern outdoor lifestyle category, such as sandals, shoes, and boots. The Sanuk Brand segment originated in Southern California surf culture and has emerged into a lifestyle brand with a presence in the relaxed casual shoe and sandal categories. The Other Brands segment includes the Koolaburra by UGG brand. The Direct-to-Consumer segment consists of retail stores and e-commerce websites. The company was founded by Douglas B. Otto in 1973 and is headquartered in Goleta, CA.

Deckers Outdoor Corp.

Deckers Outdoor is trending as investors react to a fiscal report that beat revenue and earnings expectations, driving significant share price volatility. The community is actively debating the durability of the HOKA brand's growth and the impact of the company's aggressive share buyback strategy on long-term valuation.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending following positive Phase 3 results for its breast cancer drug gedatolisib, with community members actively discussing the potential for a commercial rollout, buyout prospects, and a possible short squeeze given the significant interest in the stock's clinical milestones. Investors are closely monitoring the company's transition into a commercial-stage firm while debating the implications of launch timing and the company's manufacturing scalability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$CYDY the ESMO poster is MIND-BOGGLING! Please read this whole post &amp; view the screenshot of the ESMO poster. 
 
5 patients out of 26 (2 unknown PD-L1 levels) had  
PD-L1 level (CPS) &gt; or = 10%  
 
All 5 of these patients dosed w Leronlimab are alive today!  
&gt;48 months ago 
 
Overall survival 48 months &amp; counting! 
 
So I found this from NIH on the prevalence of PD-L1 expression in tNBC: 
In TNBC, the percentage of patients with PD-L1 expression above 10% (CPS ≥ 10) is approximately 30-40%. For patients with PD-L1 CPS ≥ 10, treatment with pembrolizumab plus chemotherapy improves overall survival, with a median OS of 23 months compared to 16.1 months with chemotherapy alone.  
 
pembrolizumab=Keytruda 
OS=23 months  
 
Leronlimab OS=over 48 mths &amp; counting 🤯 
 
Keytruda estimated revenue in 2024 = $29.5 billion 
 
Our market cap is $.5 billion 
WTF 🤔 
 
Me thinks there&#39;s an imbalance here &amp; quite the opportunity to make a butt ton of $! 
 
My mind is blown away! Looking forward to realization of the imbalance from the market!

John canoli

Langly_7722

nyasaland

Maggie16

Nadia Karmo-Clark

Kevin Chant

Steven feldman

Syco Dyne

Thomas Migliara

Albert Harris

Joe Blow

Saucier

Zion

anh vo

Thomas H Butcher

George Plympton

Rich F

UseToBe4RingsPatsRule

skilachi19

Ant Car

thriving

CGC Cassell

Dae Mon

christopher

T Lindsay

Mark

StockTwits Web

CytoDyn Inc

 the ESMO poster is MIND-BOGGLING! Please read this whole post & view the screenshot of the ESMO poster. 
 
5 patients out of 26 (2 unknown PD-L1 levels) had  
PD-L1 level (CPS) > or = 10%  
 
All 5 of these patients dosed w Leronlimab are alive today!  
>48 months ago 
 
Overall survival 48 months & counting! 
 
So I found this from NIH on the prevalence of PD-L1 expression in tNBC: 
In TNBC, the percentage of patients with PD-L1 expression above 10% (CPS ≥ 10) is approximately 30-40%. For patients with PD-L1 CPS ≥ 10, treatment with pembrolizumab plus chemotherapy improves overall survival, with a median OS of 23 months compared to 16.1 months with chemotherapy alone.  
 
pembrolizumab=Keytruda 
OS=23 months  
 
Leronlimab OS=over 48 mths & counting 🤯 
 
Keytruda estimated revenue in 2024 = $29.5 billion 
 
Our market cap is $.5 billion 
WTF 🤔 
 
Me thinks there's an imbalance here & quite the opportunity to make a butt ton of $! 
 
My mind is blown away! Looking forward to realization of the imbalance from the market!